enGene Therapeutics Inc.
ENGNHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeenGene Therapeutics Inc. enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. Valued at $123.9M, ENGN is a micro-cap name in its sector. The company develops genetic medicines to help patients suffering from bladder cancer.
Market Cap
$123.9M
Beta
-0.01
P/E (TTM)
—
P/E (Fwd)
-0.93
EPS (TTM)
$-2.25
EPS (Fwd)
$-1.99
ROE
-46.1%
ROA
-25.6%
Cash
$275.9M
Total Debt
$33.5M
Free CF
-$65.3M
52W Change
-53.5%
Annual Financials
Cash vs Debt
enGene Therapeutics Inc. holds $275.9M in cash against $33.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$65.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -46.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, enGene Therapeutics Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, ENGN has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence enGene Therapeutics Inc.'s trajectory.